Roflumilast (Daxas®)

Assessment Status Full HTA Assessment
Drug Roflumilast
Brand Daxas®
Indication For the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.
Assessment Process
Full submission received from Applicant 11/06/2010
NCPE assessment completed 03/11/2010
NCPE assessment outcome Reimbursement not Recommended

We do not recommend reimbursement of Roflumilast (Daxas®) under the Community Drugs Schemes.

Technical Summary